Mark A. Velleca
2019 - G1 Therapeutics
Compensation breakdown
| Non-Equity Incentive Plan | $280,108 |
|---|---|
| Option Awards | $3,105,237 |
| Salary | $589,700 |
| Other | $8,400 |
| Total | $3,983,445 |
Velleca received $3.1M in option awards, accounting for 78% of the total pay in 2019.
Velleca also received $280.1K in non-equity incentive plan, $589.7K in salary and $8.4K in other compensation.
Rankings
In 2019, Mark A. Velleca's compensation ranked 3,001st out of 13,971 executives tracked by ExecPay. In other words, Velleca earned more than 78.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,001 out of 13,971 | 79th |
Division Manufacturing | 1,082 out of 5,701 | 81st |
Major group Chemicals And Allied Products | 359 out of 2,200 | 84th |
Industry group Drugs | 294 out of 1,886 | 84th |
Industry Pharmaceutical Preparations | 216 out of 1,398 | 85th |
Pay ratio
| Mark A. Velleca's Pay | $3,983,445 |
|---|---|
| Median Employee's Pay | $213,060 |
| Pay Ratio | 19to 1 |
In 2019, the annual total compensation of Mark A. Velleca was $3,983,445.
The annual total compensation of the median employee at G1 Therapeutics was $213,060.
The ratio of Mark A. Velleca's pay to the pay of median employee was therefore 19 to one.
Velleca's colleagues
We found five more compensation records of executives who worked with Mark A. Velleca at G1 Therapeutics in 2019.
2019
Mark Avagliano
G1 Therapeutics
Chief Business Officer
2019
Jennifer Moses
G1 Therapeutics
Chief Financial Officer
2019
Rajesh Malik
G1 Therapeutics
Chief Medical Officer
2019
John Demaree
G1 Therapeutics
Chief Commercial Officer
2019
Barclay Phillips
G1 Therapeutics
Chief Financial Officer
News
April 24, 2024
April 28, 2021
April 24, 2020
April 30, 2019